▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3168 by analyst upside · 2026-10-16
ABT
Abbott Laboratories
Healthcare · Market Cap $181B · P/E 33.8x
ANALYST PRICE TARGET
+15.3%
implied upside to consensus target
Current Price $104.68
Consensus Target $120.72
Bull Target $135.0
Bear Target $103.0
Analysts Covering 26
ANALYST CONSENSUS - BUY
Strong Buy
5
Buy
18
Hold
4
Sell
0
52-Week Low $81.97
52-Week High $132.03
YTD Return -13.6%
FUNDAMENTALS
Market Cap $181B
P/E Ratio (TTM) 33.8x
Forward P/E 17.3x
EPS (TTM) $3.10
PEG Ratio 1.89
Dividend Yield 2.41%
Revenue (TTM) $46.6B
Profit Margin 11.6%
52-WEEK RANGE
52-Week Low $81.97
52-Week High $132.03
Current Price $104.68
Bear Target $103.0
Bull Target $135.0
● Now $104.68 ● Target $120.72
TRADING DATA
Avg Volume 9.4M
YTD Return -13.6%
Analyst Count 26
Consensus Buy
Upside to Target +15.3%
Last Updated 2026-10-16

ANALYST SUMMARY

Abbott Laboratories (ABT) is currently trading at $104.68 with a Wall Street consensus price target of $120.72, implying potential upside of 15.3% over the next 12 months. 26 analysts currently cover ABT, with a consensus rating of Buy - 85% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $135.0, while the most cautious has a target of $103.0.

ABT operates in the Healthcare sector with a market capitalisation of $181B. The stock is down 13.6% year-to-date and is currently trading near the lower end of its 52-week range of $81.97 – $132.03.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ABT, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Barclays ● Initiated
Overweight 2026-10-07 Building track record
Rothschild & Co ↑ Upgrade
Neutral → Buy 2026-10-02 Building track record
TD Cowen reit
Buy → Buy 2026-09-08 Building track record
TD Cowen - Reiterated
Buy → Buy 2026-08-25 Building track record
TD Cowen - Reiterated
Buy → Buy 2026-08-21 Building track record
Citigroup - Reiterated
Buy → Buy 2026-08-14 Building track record
Wolfe Research ↑ Upgrade
Peer Perform → Outperform 2026-08-13 Building track record
UBS - Reiterated
Buy → Buy 2026-07-28 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
71
out of 100
Coverage depth
25/30
Consensus clarity
24/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →